- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Genflow Biosciences hails data from trial of dog ageing gene therapy | 1 | Alliance News | ||
| Fr | Genflow Biosciences PLC Announces Update on Animal Health Program | 130 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Fr | Genflow Biosciences - Update on Animal Health Program | 1 | RNS | ||
| Do | Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification | 153 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Do | Genflow Biosciences - Update, Equity Issue and PDMR Notification | 1 | RNS | ||
| 02.10. | Genflow Biosciences PLC Announces Issue of Equity | 262 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 02.10. | Genflow Biosciences - Issue of Equity - Correction | 2 | RNS | ||
| 02.10. | SMALL-CAP WINNERS & LOSERS: Argo Blockchain up; Genflow issues shares | 24 | Alliance News | ||
| 02.10. | Genflow Biosciences - Issue of Equity | 2 | RNS | ||
| 30.09. | Genflow Biosciences PLC Announces Half-Year Report | 371 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.Chairman's StatementIt... ► Artikel lesen | |
| 30.09. | Genflow Biosciences - Half-year Report | 1 | RNS | ||
| 19.09. | Genflow Biosciences PLC Announces Holding(s) in Company | 226 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 19.09. | Genflow files patent examination request in China for NASH treatment | 4 | Investing.com | ||
| 19.09. | Genflow treibt Patent für NASH-Behandlung in China voran | 2 | Investing.com Deutsch | ||
| 19.09. | Genflow Biosciences PLC: Genflow Strengthens IP Portfolio | 176 | ACCESS Newswire | Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire / September 19, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF)... ► Artikel lesen | |
| 19.09. | Genflow Biosciences - Genflow Strengthens IP Portfolio | 1 | RNS | ||
| 15.09. | Genflow schließt Vertraulichkeitsabkommen mit führenden Tiergesundheitsunternehmen | 2 | Investing.com Deutsch | ||
| 15.09. | Genflow signs confidentiality deals with animal health companies | 1 | Investing.com | ||
| 15.09. | Genflow Biosciences PLC: Genflow Signs CDAs with Animal Health Companies | 249 | ACCESS Newswire | Genflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform LONDON, UK / ACCESS Newswire / September 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow"... ► Artikel lesen | |
| 15.09. | Genflow Biosciences - Genflow Signs CDAs with Animal Health Companies | - | RNS |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 48,960 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,550 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| NUVALENT | 89,75 | 0,00 % | Nuvalent präsentiert neue Daten zu HER2-Inhibitor auf Krebskonferenz | ||
| TARSUS PHARMACEUTICALS | 70,34 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| ARCELLX | 86,23 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,720 | 0,00 % | Zoryve-Umsätze: Mizuho hebt Kursziel für Arcutis Biotherapeutics auf 26 $ | ||
| BEAM THERAPEUTICS | 25,390 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| COGENT BIOSCIENCES | 16,200 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CG ONCOLOGY | 42,960 | 0,00 % | Why Cg Oncology Stock Rocketed 7% Higher Today | ||
| LENZ THERAPEUTICS | 38,610 | 0,00 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 43,050 | 0,00 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,030 | 0,00 % | Dyne cut to Perform at Oppenheimer on valuation | ||
| TREVI THERAPEUTICS | 9,710 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,710 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,014 (+90,32 %) liegt der Kurs bei 0,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.